|
RO-3306
- 英文名称：RO-3306
- 品牌：WYTSCI
- 产地：进口
- 型号：1MG
- 货号：WT-AY-B11125
- cas：872573-93-8
- 价格： ￥1/mg
- 发布日期： 2025-04-10
- 更新日期： 2025-05-23
产品详请
| 产地 | 进口 |
| 品牌 | WYTSCI |
| 货号 | WT-AY-B11125 |
| 用途 | 科研检测 |
| 英文名称 | RO-3306 |
| 包装规格 | 1MG |
| CAS编号 | 872573-93-8 |
| 别名 | RO-3306 |
| 纯度 | 98+% |
| 分子式 | |
| 是否进口 | 是 |
纯度:98% by HPLC;NMR (Conforms)
分子式:C18H13N3OS2
分子量:351.45
溶剂:DMSO (15 mg/ml)
性状:Off-white or pale yellow solid
存储:-20°C
Activity (short version):CDK1 inhibitor
Function / Pharmacology:RO-3306 is a selective inhibitor of CDK1 (IC50 = 35 nM versus CDK2 IC50 = 340nM).1,2 It induces G2/M phase cell cycle arrest and apoptosis. Inhibition of CDK1 with RO-3306 has been shown to have synergistic effects with PARP inhibitors in treating various breast cancers.3,4 It has also been demonstrated to overcome apoptotic resistance in BRAFV600E human colorectal cancer cells.5
分子式:C18H13N3OS2
分子量:351.45
溶剂:DMSO (15 mg/ml)
性状:Off-white or pale yellow solid
存储:-20°C
Activity (short version):CDK1 inhibitor
Function / Pharmacology:RO-3306 is a selective inhibitor of CDK1 (IC50 = 35 nM versus CDK2 IC50 = 340nM).1,2 It induces G2/M phase cell cycle arrest and apoptosis. Inhibition of CDK1 with RO-3306 has been shown to have synergistic effects with PARP inhibitors in treating various breast cancers.3,4 It has also been demonstrated to overcome apoptotic resistance in BRAFV600E human colorectal cancer cells.5
